Decitabine modulates dopamine agonist sensitivity in gh3 rat pituitary tumor cells via Trim7
Xu Zhang, Tengwu Chang, Jinyong Li, Hua Gao, Wenju Bai, Hao Yue, Cheng Zhang, Peikun Zhang, Yuanyan Ge, Jichao Wang · 2026
Read Decitabine modulates dopamine agonist sensitivity in gh3 rat pituitary tumor cells via Trim7 by Xu Zhang, Tengwu Chang, Jinyong Li, Hua Gao, Wenju Bai, Hao Yue, Cheng Zhang, Peikun Zhang, Yuanyan Ge, Jichao Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13629320.txt.
Description
Xu Zhang and co-authors probe in 2026 why some pituitary tumors resist their standard drug. Prolactin-secreting tumors are usually treated first with dopamine agonists, but a share of patients respond poorly. Working with rat pituitary tumor cells, the team tested a drug that strips chemical marks from DNA.
Gene scans after treatment pointed to one gene, Trim7. Cells made to produce extra Trim7 died more readily when given the standard drug cabergoline. Growth slowed too, though not decisively. The authors frame the link as suggestive, not proven, and call for tests that remove the gene. Still, Trim7 stands out as a possible target for resistant tumors.
Catalog record
| CREATOR | Xu Zhang, Tengwu Chang, Jinyong Li, Hua Gao, Wenju Bai, Hao Yue, Cheng Zhang, Peikun Zhang, Yuanyan Ge, Jichao Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |